Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Crimmitschau – page 3

317 clinical trials in Crimmitschau, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Crimmitschau at a glance
317
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

317 trials in Crimmitschau

Open in trial search

First-line treatment of metastatic non‑small cell lung cancer with high PD‑L1 expression: ivonescimab versus pembrolizumab

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivonescimab
  • Sponsor:Summit Therapeutics Inc.

Phase 2 Study of Oral VS-7375 in Adults with Advanced KRAS G12D‑Mutated Non‑Small Cell Lung Cancer Previously Treated

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GFH375
  • Sponsor:Verastem Inc.

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Study on JX10 for Improving Outcomes in Patients with Acute Ischemic Stroke

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:JX10
  • Sponsor:Corxel Pharmaceuticals Co. Ltd.

Study on the Safety and Effectiveness of Sovateltide for Patients with Acute Ischemic Stroke

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sovateltide
  • Sponsor:Pharmazz EU Limited

Study of Orforglipron in Overweight Adults at Risk of Developing Obesity‑Related Complications or Class 1 Obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Obesity

Recruiting

Long‑term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Asthma

Recruiting

Study of Beclometasone Dipropionate in Patients with Asthma to Evaluate Disease Characteristics and Control

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Efficacy and Safety of Amara‑Tropfen Dilution vs Placebo in Patients with Irritable Bowel Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Artemisia absinthium, herba REC., ethanol. EXTR. 1:2,3
  • Sponsor:Weleda AG

Randomized trial of irinotecan drug combination versus standard therapy as first-line treatment in patients with locally advanced or metastatic small bowel adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Crimmitschau

What the registry says about research in the country

01 Dermatological Conditions

Research focusing on treatment options for atopic dermatitis, evaluating the effectiveness of methylprednisolone aceponate cream formulations in patients with mild to moderate symptoms.

  • Comparative effectiveness studies
  • Topical treatments
  • Anti-inflammatory therapies

Clinical assessments aim to enhance therapeutic options for skin inflammation management.

02 Fungal Skin Infections

Investigation of combination therapy using clotrimazole and betamethasone dipropionate for treating moderate to severe fungal skin infections, particularly focusing on candidiasis.

  • Antifungal treatments
  • Combined therapeutic approaches
  • Inflammatory control

Studies evaluate innovative treatment formulations for enhanced patient outcomes.

03 Facial Skin Disorders

Clinical evaluation of ivermectin-based treatments for papulopustular rosacea, comparing novel formulations with established therapies to reduce inflammatory lesions.

  • Rosacea management
  • Anti-inflammatory effects
  • Facial lesion reduction

Research focuses on improving therapeutic options for facial inflammatory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.